Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) (NCT06634875)
A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination With Pembrolizumab in Patients With Metastatic or Unresectable, Locally Advanced Colorectal Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.
Who can join: Review the eligibility criteria below.
Location: USC/Norris Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- USC/Norris Cancer Center — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
📞 Contact the Study Coordinator
Phone: +46 763 103031
Email: info@buzzardpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Cancer Metastatic
- Assessing How Normal Variations in CT Scanning Affects Its Interpretation — New York, New York
- A Phase 1b Study of WU-NK-101 in Combination With Cetuximab — San Francisco, California
- BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases — La Jolla, California
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis — Lake Success, New York
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases — New York, New York
Explore by condition: All Colorectal Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.